Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenalisib with CHOP for Peripheral T-cell Lymphoma
NCT05239910Phase 2Withdrawn
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tenalisib in peripheral T-cell lymphoma (PTCL), sponsored by Rhizen Pharmaceuticals AG. Planned start Jan 2023; status: withdrawn.
02
Drugs
tenalisib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05239910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239910.